News

As per the agreement, cancer vaccine experts at RUMC are expected to perform exploratory studies on Homspera relating to its adjuvant and immunomodulatory properties for potential application in

Protalix BioTherapeutics said that it has made the submission in response to a request from the FDA for validation data from its upgraded manufacturing facility. The FDA is

Invida is expected to be in charge of filing and commercialising the drugs in different countries. The agreement is for an initial period of five years renewable for

Takeda’s Nesina is a selective DPP-4 inhibitor for the treatment of type 2 diabetes. PPD’s compound partnering division collaborated with Takeda to develop the product. As part of

HST Global said that with Benson’s assistance, it plans to license the ‘FIT’ protocol, as well as other pending protocols, to clinical treatment facilities in both Panama and

PPD said that the new facility will offer product and analytical development services, including method development; validation; stability, release and quality control testing; and global clinical supplies services,

PPD posted a net income of $17.2m for the first quarter 2010, or $0.14 per diluted share, compared to $45.14m, or $0.38 per diluted share, for the prior

Watson’s ANDA is for the generic equivalent of Teva’s Cenestin. The suit was filed on April 23, 2010, in the US District Court for the District of New

Shady Grove Fertility claimed that the new technology named ‘flash freezes’ increases chances of woman having her own biological children well past the age of peak fertility. Shady